Polycystic Ovary SyndromeGLCNCT02630485
Graceful Lifestyle Changes Study for PCOS and Infertility
A study testing Graceful Lifestyle Changes, Myo-inositol and Letrozole in people with Polycystic Ovary Syndrome and Infertility, run by University of British Columbia.
Trial summary
The purpose of this study is to help women with PCOS to improve their symptoms and ovulation rate through a lifestyle intervention program which introduces a specific diet, a physical activity regimen and mindfulness exercises to improve psychological well-being and overall health. Read more about this study
- Who is it for?
- Ages 18 to 37 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Polycystic Ovary Syndrome, Infertility
- What is being tested?
- Graceful Lifestyle Changes, Myo-inositol and Letrozole
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 240 participants
- Where
- No sites listed yet
- Study dates
- Dec 2015to Aug 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 37 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- all women with PCOS trying to conceive who are between 18 and 37 years of age (PCOS will be defined using the Rotterdam criteria)
Who cannot join
- women who have already began fertility treatment
- women who are taking myo-inositol or have taken it in the past three months
- women being treated for or who have a history of an eating disorder
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility
The purpose of this study is to help women with PCOS to improve their symptoms and ovulation rate through a lifestyle intervention program which introduces a specific diet, a physical activity regimen and mindfulness exercises to improve psychological well-being and overall health.
Read the detailed description
- Purpose
The purpose of this study is to:
- assess if implementing lifestyle changes through instruction and coaching is as effective as standard ovulation-induction therapy,
- evaluate if myo-inositol is an effective addition to both lifestyle intervention and standard fertility medications, and
- evaluate how each of four main sub-types of PCOS will respond to our lifestyle intervention program.
- Hypothesis:
The investigators hypothesize that implementing lifestyle changes in women with PCOS will help restore ovulation by balancing reproductive hormones and increasing sensitivity to insulin. Lifestyle changes will also help to manage common PCOS symptoms and therefore, increase psychological well-being and quality of life in this population of women. In addition to a low-glycemic diet, physical activity, and stress reduction, a diet supplemented with myo-inositol will create further hormonal homeostasis and improve metabolic functioning. Finally, the investigators believe that the distinct sub-types of PCOS will respond differently to the proposed lifestyle intervention program and therefore, this will demonstrate that diet, activity and stress reduction is an effective approach to fertility for some individuals, but not others.
- Justification:
Polycystic ovary syndrome (PCOS) is a heterogenous condition characterized by chronic anovulation and increased androgens (either as clinical or biochemical manifestations) according to the original NIH criteria. Since then, polycystic ovaries on ultrasound assessment has been included as an additional feature in the Rotterdam criteria and a diagnosis is made if a woman has any two of these three features. Very little information is known about why PCOS can present differently among individuals and which lifestyle factors are the cause or the effect. Many women with PCOS have difficulty conceiving due to infrequent ovulation. Evidence suggest that diet, activity and stress levels influence ovulation and affect the response of the ovaries to fertility medications or pregnancy success to fertility treatments.
To this date, there have been no studies conducted incorporating diet, exercise, and stress reduction in a cohesive intervention program for women with PCOS trying to conceive. Recent studies have suggested that women with PCOS can significantly benefit from specific lifestyle changes such as eating a low glycemic diet, increasing activity level, and reducing stress however, these studies have had several limitations such as high-drop out rates, lack of PCOS phenotypes included, and small cohort sizes. Also, most studies have focused on only one major lifestyle change, such as diet, which is not as powerful as combining diet, exercise and stress reduction. Finally, mindfulness and meditation as a means to decrease stress has yet to be studied in a PCOS cohort. The relaxation response is a powerful tool that has been proven to be effective in stress-related diseases such as cancer, cardiovascular disease and mental disorders. Since women with PCOS tend to have high levels of stress, inducing the relaxation response through mindfulness may be an effective treatment for this cohort.
- Objectives
- To determine if lifestyle changes are effective at restoring ovulation without the use of a commonly used fertility treatment.
- To determine if myo-inositol improves the restoration of ovulation and insulin resistance in women with polycystic ovary syndrome (PCOS).
- To evaluate how each of four main sub-types of PCOS will respond to our lifestyle intervention program.
- Research Method:
Women with PCOS will be randomly assigned to one of two groups: the GLC group, which will participate in our "Graceful Lifestyle Changes" program and an oral fertility medication group, which will be prescribed letrozole. Within each of these two groups, participants will be further divided randomly to consume either myo-inositol or a placebo.
The GLC group will meet with physicians and educators, in small groups of 8-10 participants, once a week for 12 weeks. Each week will consist of an educational portion which will coach women on how to consume a low-glycemic diet, the benefits of walking 10,000 steps a day, and how to induce the relaxation response to decrease stress. A wellness booklet designed and provided by clinicians at Grace Fertility Centre will outline the main ideas being taught. Participants in the GLC group will be required to record their daily food intake to maintain a daily target of 45% carbohydrates and 55 grams of glycemic load a daily, which is similar to previous low-glycemic diet intervention studies. Lists will be provided outlining foods that are either low, medium, or high in glycemic load. Participants will be advised to eat as many low glycemic foods as possible and to limit the high glycemic load foods. They will also be provided with a pedometer to measure the number of steps being walked each day. Lastly, these participants will practice relaxation response exercises for twenty minutes each day and will record which exercises they performed in their daily diary.
Participants will complete a 3-day diet diary report as well as a physical activity report based on their pedometer recordings during the baseline, 4th, 8th, and 12th weeks. Participants will also receive a phone call from a trained researcher to complete a 24-hour diet recall at the end of the 2nd, 6th, and 10th weeks. This recall will assess all food consumed in the previous 24 hours. These combined methods will aim to:
- assess overall compliance to the low-glycemic diet
- provide information on the length of time participants take to comply
- evaluate any fluctuations in eating habits
- compare two types of nutritional assessment to each other
Compliance to the physical activity portion will be measured through daily pedometer recordings made by the participant. Compliance to the meditation and relaxation exercises will be measured by daily reports. Compliance will be ensured additionally through weekly check-ins/weigh-ins, weekly education sessions, and frequent email reminders with tips and motivators to stay on track.
The use of clomiphene citrate to treat anovulatory infertility is common. However, in agreement with what the investigators have observed in clinical practice, recent evidence has suggested that letrozole is more effective than clomiphene citrate in achieving ovulation. Additionally, letrozole may be more beneficial since it does not negatively affect the endometrial thickness. However, up to 40% of women may not ovulate with oral fertility treatments alone. Newer evidence suggests that diet, activity and stress levels influence ovulation and affect the response of the ovaries to fertility treatments.
- Conditions
- Polycystic Ovary Syndrome, Infertility
- Being tested
- Graceful Lifestyle Changes, Myo-inositol, Letrozole
- Keywords
- Randomized Controlled Trial
- Medical subject headings
- Polycystic Ovary Syndrome, Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Graceful Lifestyle ChangesBehavioural
Also called GLC
Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
Myo-inositolDietary supplement
Also called Inositol, MYO
Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
LetrozoleDrug
Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
| Study group | Role | What they receive |
|---|---|---|
| Graceful Lifestyle Changes & MYO | Experimental | The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.
In addition, this group will take myo-inositol (6 grams in juice or water every morning). Receives: Behavioral: Graceful Lifestyle Changes; Dietary Supplement: Myo-inositol |
| Graceful Lifestyle Changes | Experimental | The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.
In addition, this group will take a white powder placebo (6 grams in juice or water every morning). Receives: Behavioral: Graceful Lifestyle Changes |
| Letrozole & MYO | Placebo comparator | The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
In addition, this group will take myo-inositol (6 grams in juice or water every morning). Receives: Dietary Supplement: Myo-inositol; Drug: Letrozole |
| Letrozole | Placebo comparator | The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
In addition, this group will take a white powder placebo (6 grams in juice or water every morning). Receives: Drug: Letrozole |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ovulation Occurence
Ovulation is the primary outcome and expressed as any ovulation (categorical "yes" or "no") during the 12-week (84-day) study. This length allows observation of 3 potential ovulatory cycles. The upper limit of a normal ovulatory cycle is 35 days, so to accommodate for this, documentation of ovulation with a progesterone test may extend to the end of week 14.
Measured: 12 weeks
Ovulation Frequency
Ovulation is the primary outcome can be expressed in according to frequency (nominal "0", "1", "2, or "3") during the 12-week (84-day) study. This length allows observation of 3 potential ovulatory cycles. The upper limit of a normal ovulatory cycle is 35 days, so to accommodate for this, documentation of ovulation with a progesterone test may extend to the end of week 14.
Measured: 12 weeks
Secondary outcomes (5)
Conception
If ovulation occurs but menses does not follow, a pregnancy test will be administered.
Measured: 12 weeks
Stress
Stress will be assessed by the Depression Anxiety and Stress Scale (DASS) at the beginning and end of the 12 weeks.
Measured: 12 weeks
Anxiety
Anxiety will be assessed by the Depression Anxiety and Stress Scale (DASS) at the beginning and end of the 12 weeks.
Measured: 12 weeks
Depression
Depression will be assessed by the Depression Anxiety and Stress Scale (DASS) at the beginning and end of the 12 weeks.
Measured: 12 weeks
Quality of Life
Quality of life will be assessed by the Fertility Quality of Life Questionnaire (FertiQoL) at the beginning and end of the 12 weeks..
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2015 (estimated)
- Study startDec 2015
- Primary completionMar 2018 (estimated)
- Study completionAug 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Polycystic Ovary SyndromeStudies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anthony P Cheung, MBBS MPH MBA, Principal investigator, Grace Fertility Centre & Reproductive Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02630485
- Sponsor's protocol ID
- H13-02964
- Acronym
- GLC
- Status last verified
- Dec 2015
- First submitted
- 30 Nov 2015
- Last updated
- 15 Dec 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Barr S, Reeves S, Sharp K, Jeanes YM. An isocaloric low glycemic index diet improves insulin sensitivity in women with polycystic ovary syndrome. J Acad Nutr Diet. 2013 Nov;113(11):1523-1531. doi: 10.1016/j.jand.2013.06.347. Epub 2013 Aug 30.
PubMed 23999280Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod. 2007 Aug;22(8):2279-86. doi: 10.1093/humrep/dem108. Epub 2007 May 30.
PubMed 17537782Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.
PubMed 19499845Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. doi: 10.1210/edrv.18.6.0318.
PubMed 9408743Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Jan;96(1):E48-56. doi: 10.1210/jc.2010-0828. Epub 2010 Oct 6.
PubMed 20926534Ludwig DS, Kabat-Zinn J. Mindfulness in medicine. JAMA. 2008 Sep 17;300(11):1350-2. doi: 10.1001/jama.300.11.1350. No abstract available.
PubMed 18799450Matchim Y, Armer JM, Stewart BR. Effects of mindfulness-based stress reduction (MBSR) on health among breast cancer survivors. West J Nurs Res. 2011 Dec;33(8):996-1016. doi: 10.1177/0193945910385363. Epub 2010 Oct 18.
PubMed 20956583Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007 Dec;23(12):700-3. doi: 10.1080/09513590701672405. Epub 2007 Oct 10.
PubMed 17952759Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 Jul;28(7):509-15. doi: 10.3109/09513590.2011.650660. Epub 2012 Feb 1.
PubMed 22296306Cutler DA, Shaw AK, Pride SM, Bedaiwy MA, Cheung AP. A randomized controlled trial comparing lifestyle intervention to letrozole for ovulation in women with polycystic ovary syndrome: a study protocol. Trials. 2018 Nov 16;19(1):632. doi: 10.1186/s13063-018-3009-5.
PubMed 30445999
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility
- ClinicalTrials.gov ID
- NCT02630485
- Acronym / sponsor ID
- GLC / H13-02964
- Conditions
- Polycystic Ovary Syndrome, Infertility
- Keywords
- Randomized Controlled Trial
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- Mar 2018 (estimated)
- Study completion
- Aug 2018 (estimated)
- First posted
- 15 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to help women with PCOS to improve their symptoms and ovulation rate through a lifestyle intervention program which introduces a specific diet, a physical activity regimen and mindfulness exercises to improve psychological well-being and overall health.
Detailed description
- Purpose
The purpose of this study is to:
- assess if implementing lifestyle changes through instruction and coaching is as effective as standard ovulation-induction therapy,
- evaluate if myo-inositol is an effective addition to both lifestyle intervention and standard fertility medications, and
- evaluate how each of four main sub-types of PCOS will respond to our lifestyle intervention program.
- Hypothesis:
The investigators hypothesize that implementing lifestyle changes in women with PCOS will help restore ovulation by balancing reproductive hormones and increasing sensitivity to insulin. Lifestyle changes will also help to manage common PCOS symptoms and therefore, increase psychological well-being and quality of life in this population of women. In addition to a low-glycemic diet, physical activity, and stress reduction, a diet supplemented with myo-inositol will create further hormonal homeostasis and improve metabolic functioning. Finally, the investigators believe that the distinct sub-types of PCOS will respond differently to the proposed lifestyle intervention program and therefore, this will demonstrate that diet, activity and stress reduction is an effective approach to fertility for some individuals, but not others.
- Justification:
Polycystic ovary syndrome (PCOS) is a heterogenous condition characterized by chronic anovulation and increased androgens (either as clinical or biochemical manifestations) according to the original NIH criteria. Since then, polycystic ovaries on ultrasound assessment has been included as an additional feature in the Rotterdam criteria and a diagnosis is made if a woman has any two of these three features. Very little information is known about why PCOS can present differently among individuals and which lifestyle factors are the cause or the effect. Many women with PCOS have difficulty conceiving due to infrequent ovulation. Evidence suggest that diet, activity and stress levels influence ovulation and affect the response of the ovaries to fertility medications or pregnancy success to fertility treatments.
To this date, there have been no studies conducted incorporating diet, exercise, and stress reduction in a cohesive intervention program for women with PCOS trying to conceive. Recent studies have suggested that women with PCOS can significantly benefit from specific lifestyle changes such as eating a low glycemic diet, increasing activity level, and reducing stress however, these studies have had several limitations such as high-drop out rates, lack of PCOS phenotypes included, and small cohort sizes. Also, most studies have focused on only one major lifestyle change, such as diet, which is not as powerful as combining diet, exercise and stress reduction. Finally, mindfulness and meditation as a means to decrease stress has yet to be studied in a PCOS cohort. The relaxation response is a powerful tool that has been proven to be effective in stress-related diseases such as cancer, cardiovascular disease and mental disorders. Since women with PCOS tend to have high levels of stress, inducing the relaxation response through mindfulness may be an effective treatment for this cohort.
- Objectives
- To determine if lifestyle changes are effective at restoring ovulation without the use of a commonly used fertility treatment.
- To determine if myo-inositol improves the restoration of ovulation and insulin resistance in women with polycystic ovary syndrome (PCOS).
- To evaluate how each of four main sub-types of PCOS will respond to our lifestyle intervention program.
- Research Method:
Women with PCOS will be randomly assigned to one of two groups: the GLC group, which will participate in our "Graceful Lifestyle Changes" program and an oral fertility medication group, which will be prescribed letrozole. Within each of these two groups, participants will be further divided randomly to consume either myo-inositol or a placebo.
The GLC group will meet with physicians and educators, in small groups of 8-10 participants, once a week for 12 weeks. Each week will consist of an educational portion which will coach women on how to consume a low-glycemic diet, the benefits of walking 10,000 steps a day, and how to induce the relaxation response to decrease stress. A wellness booklet designed and provided by clinicians at Grace Fertility Centre will outline the main ideas being taught. Participants in the GLC group will be required to record their daily food intake to maintain a daily target of 45% carbohydrates and 55 grams of glycemic load a daily, which is similar to previous low-glycemic diet intervention studies. Lists will be provided outlining foods that are either low, medium, or high in glycemic load. Participants will be advised to eat as many low glycemic foods as possible and to limit the high glycemic load foods. They will also be provided with a pedometer to measure the number of steps being walked each day. Lastly, these participants will practice relaxation response exercises for twenty minutes each day and will record which exercises they performed in their daily diary.
Participants will complete a 3-day diet diary report as well as a physical activity report based on their pedometer recordings during the baseline, 4th, 8th, and 12th weeks. Participants will also receive a phone call from a trained researcher to complete a 24-hour diet recall at the end of the 2nd, 6th, and 10th weeks. This recall will assess all food consumed in the previous 24 hours. These combined methods will aim to:
- assess overall compliance to the low-glycemic diet
- provide information on the length of time participants take to comply
- evaluate any fluctuations in eating habits
- compare two types of nutritional assessment to each other
Compliance to the physical activity portion will be measured through daily pedometer recordings made by the participant. Compliance to the meditation and relaxation exercises will be measured by daily reports. Compliance will be ensured additionally through weekly check-ins/weigh-ins, weekly education sessions, and frequent email reminders with tips and motivators to stay on track.
The use of clomiphene citrate to treat anovulatory infertility is common. However, in agreement with what the investigators have observed in clinical practice, recent evidence has suggested that letrozole is more effective than clomiphene citrate in achieving ovulation. Additionally, letrozole may be more beneficial since it does not negatively affect the endometrial thickness. However, up to 40% of women may not ovulate with oral fertility treatments alone. Newer evidence suggests that diet, activity and stress levels influence ovulation and affect the response of the ovaries to fertility treatments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Graceful Lifestyle Changes & MYO | Experimental | Behavioral: Graceful Lifestyle Changes, Dietary Supplement: Myo-inositolThe 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness. In addition, this group will take myo-inositol (6 grams in juice or water every morning). |
| Graceful Lifestyle Changes | Experimental | Behavioral: Graceful Lifestyle ChangesThe 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness. In addition, this group will take a white powder placebo (6 grams in juice or water every morning). |
| Letrozole & MYO | Placebo comparator | Dietary Supplement: Myo-inositol, Drug: LetrozoleThe women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved. In addition, this group will take myo-inositol (6 grams in juice or water every morning). |
| Letrozole | Placebo comparator | Drug: LetrozoleThe women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved. In addition, this group will take a white powder placebo (6 grams in juice or water every morning). |
Who may qualify
- Ages
- 18 to 37 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- all women with PCOS trying to conceive who are between 18 and 37 years of age (PCOS will be defined using the Rotterdam criteria)
Key exclusion criteria (3 listed)
- women who have already began fertility treatment
- women who are taking myo-inositol or have taken it in the past three months
- women being treated for or who have a history of an eating disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Graceful Lifestyle ChangesAlso: GLCParticipants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this. | Behavioural | Graceful Lifestyle Changes, Graceful Lifestyle Changes & MYO |
| Myo-inositolAlso: Inositol, MYOMyo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks. | Dietary supplement | Graceful Lifestyle Changes & MYO, Letrozole & MYO |
| LetrozoleLetrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved. | Drug | Letrozole, Letrozole & MYO |
Primary outcome
Ovulation Occurence
Time frame: 12 weeks
Ovulation is the primary outcome and expressed as any ovulation (categorical "yes" or "no") during the 12-week (84-day) study. This length allows observation of 3 potential ovulatory cycles. The upper limit of a normal ovulatory cycle is 35 days, so to accommodate for this, documentation of ovulation with a progesterone test may extend to the end of week 14.
Ovulation Frequency
Time frame: 12 weeks
Ovulation is the primary outcome can be expressed in according to frequency (nominal "0", "1", "2, or "3") during the 12-week (84-day) study. This length allows observation of 3 potential ovulatory cycles. The upper limit of a normal ovulatory cycle is 35 days, so to accommodate for this, documentation of ovulation with a progesterone test may extend to the end of week 14.
5 secondary outcomes
Conception
Time frame: 12 weeks
Stress
Time frame: 12 weeks
Anxiety
Time frame: 12 weeks
Depression
Time frame: 12 weeks
Quality of Life
Time frame: 12 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2015.
- Background: PubMed 23999280Barr S, Reeves S, Sharp K, Jeanes YM. An isocaloric low glycemic index diet improves insulin sensitivity in women with polycystic ovary syndrome. J Acad Nutr Diet. 2013 Nov;113(11):1523-1531. doi: 10.1016/j.jand.2013.06.347. Epub 2013 Aug 30.
- Background: PubMed 17537782Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod. 2007 Aug;22(8):2279-86. doi: 10.1093/humrep/dem108. Epub 2007 May 30.
- Background: PubMed 19499845Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.
- Background: PubMed 9408743Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. doi: 10.1210/edrv.18.6.0318.
- Background: PubMed 20926534Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Jan;96(1):E48-56. doi: 10.1210/jc.2010-0828. Epub 2010 Oct 6.
- Background: PubMed 18799450Ludwig DS, Kabat-Zinn J. Mindfulness in medicine. JAMA. 2008 Sep 17;300(11):1350-2. doi: 10.1001/jama.300.11.1350. No abstract available.
- Background: PubMed 20956583Matchim Y, Armer JM, Stewart BR. Effects of mindfulness-based stress reduction (MBSR) on health among breast cancer survivors. West J Nurs Res. 2011 Dec;33(8):996-1016. doi: 10.1177/0193945910385363. Epub 2010 Oct 18.
- Background: PubMed 17952759Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007 Dec;23(12):700-3. doi: 10.1080/09513590701672405. Epub 2007 Oct 10.
- Background: PubMed 22296306Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 Jul;28(7):509-15. doi: 10.3109/09513590.2011.650660. Epub 2012 Feb 1.
- Derived from this study: PubMed 30445999Cutler DA, Shaw AK, Pride SM, Bedaiwy MA, Cheung AP. A randomized controlled trial comparing lifestyle intervention to letrozole for ovulation in women with polycystic ovary syndrome: a study protocol. Trials. 2018 Nov 16;19(1):632. doi: 10.1186/s13063-018-3009-5.
Related trials for Polycystic Ovary Syndrome
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Active, not recruiting
Mindfulness-Based Education For Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS), Menstrual Symptoms
Not yet recruitingObservational study
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
Obesity & Overweight, Diabetes Mellitus, Type 2
RecruitingPhase 1
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS
Polycystic Ovary Syndrome (PCOS), Polycystic Ovary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anthony P Cheung, MBBS MPH MBA principal investigator
Grace Fertility Centre & Reproductive Medicine
Questions about this trial
What is this clinical trial studying?
A study testing Graceful Lifestyle Changes, Myo-inositol and Letrozole in people with Polycystic Ovary Syndrome and Infertility, run by University of British Columbia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Anthony P Cheung, MBBS MPH MBA (604-558-4886, ACheung@fertilitywithgrace.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ovulation Occurence (time frame: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02630485, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2015.